• 信息
  • 详情
  • 联系
  • 推荐
分享好友 产品首页 产品分类 切换频道
1/5
Recombinant Mouse Follistatin-like 5/FSTL5 Protein, CF  100 UG图1

Recombinant Mouse Follistatin-like 5/FSTL5 Protein, CF 100 UG

2024-11-24 19:55IP属地 广东省东莞市 电信00留言

9065-FN

 

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.


Reconstitution Reconstitute at 500 μg/mL in PBS.



Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.


Stability & Storage:       Use a manual defrost freezer and avoid repeated freeze-thaw cycles.      

  • 12 months from date of receipt, -20 to -70 °C as supplied.

  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.

  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


Data Images

Bioactivity      


       

Recombinant Mouse Follistatin-like 5/FSTL5 (Catalog #
9065-FN) inhibits Hep3B human hepatocellular carcinoma cell survival. The ED50 for this effect is typicallly
2-10 μg/mL.

Background: Follistatin-like 5/FSTL5

Follistatin-like 5 (FSTL5) is a secreted 94 kDa (predicted) member of the SPARC protein family (1). In its N-terminal half, FSTL5 contains a Kazal-like domain, two EF-hand domains, and two Ig-like domains. Mature mouse FSTL5 shares 91% and 97% amino acid sequence identity with human and rat FSTL5, respectively. FSTL5 is expressed in the cartilage and tendon of developing digits and the shafts of long bones (2). In the brain it is expressed in the olfactory bulb, CA3 area of the hippocampus, and granule cell layer of the cerebellum (3). FSTL5 inhibits the proliferation and promotes the apoptosis of hepatocellular carcinoma cells (4). Its expression in medulloblastoma and downregulation in hepatocellular carcinoma are associated with poor prognosis (4, 5).

举报
收藏 0
评论 0
联系方式